– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection – – Strong demand for KORSUVA injection driven by large dialysis…
STAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the…
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients…
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of…
STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the…
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – –…
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN,…
Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease…
STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve…